Corrigendum to "Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study" [Endocrine Practice 30 (2024) 424-430]
- PMID: 39023469
- DOI: 10.1016/j.eprac.2024.06.012
Corrigendum to "Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study" [Endocrine Practice 30 (2024) 424-430]
Erratum in
-
Corrigendum to "Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study" [Endocrine Practice 30 (2024) 424-430].Endocr Pract. 2025 Apr;31(4):556. doi: 10.1016/j.eprac.2025.01.006. Epub 2025 Feb 13. Endocr Pract. 2025. PMID: 39945693 No abstract available.
Erratum for
-
Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study.Endocr Pract. 2024 May;30(5):424-430. doi: 10.1016/j.eprac.2024.01.016. Epub 2024 Feb 5. Endocr Pract. 2024. PMID: 38325629
Publication types
LinkOut - more resources
Full Text Sources